High‐dose‐rate brachytherapy and hypofractionated external beam radiotherapy combined with long‐term androgen deprivation therapy for very high‐risk prostate cancer

To estimate the outcomes of high‐dose‐rate brachytherapy combined with hypofractionated external beam radiotherapy in prostate cancer patients classified as very high risk by the National Comprehensive Cancer Network.

[1]  W. Isaacs,et al.  Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy. , 2019, JCO precision oncology.

[2]  R. Hannan,et al.  Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  G. Morton,et al.  High dose-rate brachytherapy in the treatment of prostate cancer , 2018, Translational andrology and urology.

[4]  A. Kishan,et al.  External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study. , 2017, International journal of radiation oncology, biology, physics.

[5]  Pierre Thirion,et al.  Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy , 2017, BMC Urology.

[6]  Steven P. Rowe,et al.  PSMA Ligands for PET Imaging of Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[7]  Y. Tomita,et al.  Two-fraction high-dose-rate brachytherapy within a single day combined with external beam radiotherapy for prostate cancer: single institution experience and outcomes , 2016, Journal of radiation research.

[8]  Ming-Hui Chen,et al.  Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. , 2015, International journal of radiation oncology, biology, physics.

[9]  D. Grignon,et al.  Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. , 2015, International journal of radiation oncology, biology, physics.

[10]  P. Kantoff,et al.  Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease. , 2015, The Journal of urology.

[11]  F. Calvo,et al.  High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. , 2015, The Lancet. Oncology.

[12]  D. Song,et al.  Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation. , 2014, International journal of radiation oncology, biology, physics.

[13]  B. Delahunt,et al.  Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. , 2014, The Lancet. Oncology.

[14]  David C. Miller,et al.  Prostate Cancer,,Version 2.2014 Clinical Practice Guidelines in Oncology , 2014 .

[15]  Nicholas G Zaorsky,et al.  High dose rate brachytherapy boost for prostate cancer: a systematic review. , 2014, Cancer treatment reviews.

[16]  S. Kurosaka,et al.  High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up , 2013, Journal of radiation research.

[17]  Mark W. Ball,et al.  Very high risk localized prostate cancer: definition and outcomes , 2013, Prostate Cancer and Prostatic Disease.

[18]  S. van Dyk,et al.  Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer. , 2013, International journal of radiation oncology, biology, physics.

[19]  P. Hoskin,et al.  Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  F. Vicini,et al.  Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. , 2011, International journal of radiation oncology, biology, physics.

[21]  C. L. Cutajar,et al.  External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. , 2010, The Lancet. Oncology.

[22]  A. Renshaw,et al.  Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. , 2009, International journal of radiation oncology, biology, physics.

[23]  P. Scardino,et al.  Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. , 2007, The Journal of urology.

[24]  L. Egevad,et al.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma , 2005, The American journal of surgical pathology.

[25]  Y. Jo,et al.  Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer. , 2004, International journal of radiation oncology, biology, physics.

[26]  S J Damore,et al.  Needle displacement during HDR brachytherapy in the treatment of prostate cancer. , 2000, International journal of radiation oncology, biology, physics.

[27]  B. Delahunt,et al.  Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial. , 2019, The Lancet. Oncology.

[28]  C. Balch,et al.  AJCC Cancer Staging Manual. 6th ed , 2002 .

[29]  J. Cooper.  Ajcc Cancer Staging Manual , 1997 .